We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR

By LabMedica International staff writers
Posted on 01 Jul 2026

Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable PCR instruments. More...

The joint workflow is positioned to provide complete, practical, and easy-to-use DNA and RNA quantification across research settings. By combining sample preparation and analysis, the approach is designed to deliver accurate results from sample to answer.

The Maxwell System is a compact, automated benchtop instrument that uses a paramagnetic, particle-based method to purify nucleic acids. It can process up to 48 samples in parallel and is positioned as a reliable, fast, and simple solution that yields high-quality DNA and RNA suitable for a broad range of downstream applications. In this combined workflow, it serves as the front-end for consistent recovery, including from low-input materials.

Countable PCR isolates single molecules across 30 million compartments to enable true single‑molecule quantification. The system uses the majority of extracted material as input, allowing more complete interrogation of samples to maximize detection of rare targets that other methods may miss. The companies highlight applications in translational research areas such as minimal residual disease monitoring and liquid biopsy.

The offering is targeted to research use, and Countable Labs’ current products are labeled for Research Use Only (RUO). The companies state that the combined capabilities aim to deliver high sensitivity and robust scale beyond what traditional PCR methods have achieved. The co-marketing initiative brings together products and expertise to offer an end-to-end solution for DNA and RNA quantification.

Utility of the workflow was illustrated in a company poster in which circulating cell‑free DNA (cfDNA) was extracted from human plasma using a magnetic bead‑based automated method (Rapid ccfDNA Kit on the Maxwell CSC system). With a pre‑amplification step, a multiplexed KRAS assay on Countable PCR reached 0.08% mutant allele frequency (MAF) for G12C without compromising multiplexing sensitivity. Results were reproducible across technical replicates with minimal optimization.

“Countable PCR's ability to spatially isolate and detect single molecules across 30 million compartments makes it an efficient solution for a range of translational research and diagnostics challenges from monitoring minimal residual disease to pushing the boundaries of liquid biopsy,” said Anjali Pradhan, Chief Business Officer at Countable Labs. “Partnering with Promega gives our customers a seamless, end-to-end solution from sample to answer, empowering a new wave of precision medicine innovation.”

“Promega and Countable Labs are aligned in our desire to provide flexible, best-in-class, solutions for life sciences’ biggest technological challenges,” said Alok Sharma, Global Clinical Market Director at Promega. “We designed our Maxwell instruments and kits to provide the versatility our customers can trust, enabling experiments that reliably and efficiently deliver high quality nucleic acids from a broad range of sample input types and amounts, enabling many downstream applications.”

Related Links
Countable Labs
Promega


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.